Procept Biorobotics Corporation (PRCT): Why Are Short Sellers Betting Against This Hospital Tech Innovator?
We recently published a list of 10 Worst Small Cap AI Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where PROCEPT BioRobotics Corporation (NASDAQ:PRCT) stands against other worst small cap AI stocks.
The September Interest Rate Cut
Analysts have been anticipating interest rate cuts for a while now, with bets on either a 25- or a 50-basis point reduction. Concerns about potential economic instability and the impact of these cuts on net interest income for banks added complexity to the market outlook. However, the situation was sorted when the Fed cut interest rates by 50 basis points on September 18 this week, marking its first easing of monetary policy since the pandemic began.
This reduction was prompted by growing concerns about the labor market’s health. Following this decision, the Fed’s benchmark rate now stands at a range of 4.75% to 5.0%.
The Fed’s Summary of Economic Projections indicates that policymakers anticipate further cuts, with expectations of a half-point reduction by the end of this year, an additional full percentage point in 2025, and another half-point cut in 2026, ultimately targeting a range of 2.75% to 3.00%. Fed Chairman Jerome Powell stated that the projected rate cuts are not urgent and that the timing for easing is appropriate.
As political dynamics unfold ahead of the presidential elections in November, Powell emphasized that monetary policy decisions are based solely on data and economic outlooks rather than political considerations.
While a lot of analysts suggested that a 50 basis-point rate cut could be an over-exaggeration, Erika Najarian, UBS senior equity research analyst, just earlier this week, mentioned that small- and mid-cap stocks could benefit from a 50 basis-point cut. We talked about this in another one of our articles, 16 Best Mid Cap Growth Stocks To Buy Now, here’s an excerpt from it:
“Najarian attributes the recent underperformance of financial stocks to market concerns about the implications of potential rate cuts for economic stability, leading investors to question a less favorable economic outlook. She believes some anticipated cuts may already be reflected in money center bank stock prices due to their strong year-to-date performance. A 50 basis point cut could especially benefit mid-cap stocks affected by commercial real estate issues.
She explains that a 50 basis point cut would significantly impact net interest income. Money center banks benefit more from rising rates, while mid-caps are liability-sensitive and may see deposits repriced faster, favoring them if rates are cut aggressively…. She points out that banks must choose between cutting rates to remain competitive or maintaining volume, complicating forecasts for net interest income.”
Right after the Fed’s announcement, Mark Avallone, president at Potomac Wealth Advisors, discussed his reaction to the Fed’s 50 basis-point rate cut, considering the recent financial market fluctuations sparked by this decision. The move led to a volatile trading session, with the Dow Jones Industrial Average initially reaching all-time highs before briefly turning negative. By the end of the session, the Dow was up 188 points, while the S&P 500 rose by half a percent and the NASDAQ climbed approximately 0.8%.
Mark Avallone expressed surprise at the Fed’s decision but emphasized that investors shouldn’t make impulsive decisions, but rather utilize potential opportunities in small and mid-cap stocks, which he believes will benefit from a lower interest rate environment. He noted that these stocks are currently valued at about 50% of the forward price-to-earnings ratio compared to large-cap stocks, making them an attractive investment option.
Avallone warned investors to be cautious with traditional banks, especially mid-sized and large ones, based on his experience at Bank of America. He believes that the recent changes in loan pricing after the Fed’s rate cut would hurt banks’ overall revenue and income from interest. Since deposit rates are likely to stay high due to competition from non-bank financial companies and money market funds offering attractive rates above 5%, traditional banks might find it hard to stay profitable.
He suggested that it may be too late for significant moves in fixed-income investments, as many investors have already lengthened their bond durations. He recommended pausing further adjustments until it’s clear whether the rate cut is due to an economic slowdown or a preemptive action.
So, while the Fed’s interest rate cut has created uncertainty in the markets, Avallone’s analysis highlights specific sectors and strategies that could offer potential growth amid these challenges. With that context, we’re bringing you a list of the 10 worst small-cap AI stocks to buy according to short sellers to short sellers.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room.
Procept Biorobotics Corp. (NASDAQ:PRCT)
Short % of Shares Outstanding As of August 30: 11.59%
Market Capitalization as of September 14: $4.31 billion
Number of Hedge Fund Holders: 21
Procept Biorobotics Corp. (NASDAQ:PRCT) develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for minimally invasive urologic surgery, initially focused on treating benign prostatic hyperplasia. Its robotic platform utilizes advanced AI algorithms to enhance precision, minimize tissue damage, and improve surgical outcomes.
Revenue growth in Q2 2024 was driven by strong US system sales, increased utilization of existing systems, and record international revenues. The company ended this quarter with 400 US systems installed, a 72% increase year-over-year. The US monthly utilization grew by 15%. Overall, Q2 ended with a 61.17% revenue improvement year-over-year.
Despite recent challenges, the market for hospital capital investments is improving. Procept Biorobotics Corp. (NASDAQ:PRCT) is talking to hospital CFOs, who are now more open to investing in its robotic system. Growing patient demand and motivated urologists drive hospitals to prioritize this technology to remain competitive. The company’s disruptive technology can help hospitals build strong BPH practices without relying on specialists.
The prostate cancer expansion gained attention at the AUA (American Urological Association), with growing interest in Aquablation therapy. The company is enrolling patients in PRCT002, its first IDE study for prostate cancer. It has received positive coverage policies from Blue Cross Blue Shield of Arkansas and Louisiana, covering roughly 1.5 million lives.
Additionally, procedure growth is driven by new surgeons performing procedures and high surgeon retention rates (exceeding 90%). This allows the company’s team to focus on training new surgeons. The company’s strategic initiatives, including new product development, partnerships, and market expansion, are expected to strengthen its market position.
NCG Small Cap Strategy stated the following regarding PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in its Q2 2024 investor letter:
“PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a medical device company that has developed and is on the market with a robotic therapy for the treatment of BPH (benign prostatic hyperplasia). We believe PRCT has significant growth opportunity by not only taking share in the existing BPH market but by expanding the number of BPH patients treated each year and expanding into new indications, such as prostate cancer treatment, over time.”
Overall, PRCT ranks 4th on our list of 10 Worst Small Cap AI Stocks To Buy According to Short Sellers. While we acknowledge the potential of PRCT as an investment, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than PRCT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.